TACE联合RFA及自体细胞因子诱导的杀伤细胞肝动脉灌注治疗原发性肝癌的临床研究  

TACE combined with RFA and hepatic artery infusion of autologous cytokine-induced killer cells for the treatment of hepatocellular carcinoma:a clinical study

作　　者：宿敬存 赵卫[1] 胡继红[1] 易根发[1] 王彤[1] 倪慧霞 SU Jing-cun ZHAO Wei HU Ji-hong YI Gen-fa WANG Tong NI Hui-xio.(Department of Medical Imaging, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province 650032, Chin)

机构地区：[1]昆明医科大学第一附属医院医学影像科,650032

出　　处：《介入放射学杂志》2017年第1期24-29,共6页Journal of Interventional Radiology

摘　　要：目的观察TACE联合RFA和自体细胞因子诱导的杀伤细胞(CIK)肝动脉灌注治疗临床分期Ⅰ期原发性肝癌的临床疗效。方法对2009年1月至2010年5月确诊的80例行综合介入治疗的肝癌患者进行随访研究,根据是否联合CIK治疗,分为TACE联合RFA及自体CIK细胞治疗组38例(研究组),TACE联合RFA治疗组42例(对照组)。比较两组术后的生活质量(QOL)、免疫功能指标变化、无进展生存期(PFS)及生存率观察指标。结果 1QOL评分:研究组术后QOL改善明显高于对照组(P<0.05);2免疫功能:研究组和对照组免疫功能指标治疗前后对比差异有统计学意义(P<0.05),两组相比,组间差异也有统计学意义(P<0.05);3PFS和生存率:研究组和对照组的中位PFS分别为48个月和40.1个月;1、2、3、5年生存率分别为100%、89.5%、71.1%、55.3%和95.2%、88.1%、64.3%、28.6%,研究组的中位PFS和生存率高于对照组。结论 TACE联合RFA及自体CIK细胞肝动脉灌注治疗临床分期Ⅰ期的原发性肝癌能提高患者生活质量、改善患者免疫功能、延长患者的中位PFS和总生存率。Objective To observe the clinical efficacy of transcatheter arterial chemoembolization （TACE） combined with radiofrequency ablation （RFA） and hepatic artery infusion of autologous cytokine- induced killer （CIK） cells in treating clinical stage I hepatocellular carcinoma （HCC）. Methods A total of 80 patients with confirmed HCC, who were treated with comprehensive interventional therapy during the period from January 2009 to May 2010, were enrolled in this fallow-up study. The patients were divided into the study group （n=38）, receiving TACE, RFA and autologous CIK cells therapy, and the control group （n= 42）, receiving TACE and RFA only. The quality of life （QOL）, changes in immune function indexes, progression free survival （PFS） and survival rate were calculated, and the results were compared between the two groups. Results （ 1 ） QOL score： after the treatment the QOL score of the study group was significantly higher than that of the control group （P〈0.05）. （2） Immune function： the post-treatment immune function values were different from the pre-treatment ones in both groups, the differences were statistically significant （P〈O.05）; and the differences between the two groups were also statistically significant （P〈0.05）, with the changes of the study group being more obvious. （3） PFS and survival rate： the median PFS of the study group and the control group was 48.0 and 40.1 months respectively, while the one-, 2-, 3-, 5-year survival rates of the study group and the control group were 100%, 89.5%, 71.1%, 55.3% and 95.2%, 88.1%, 64.3%, 28.6% respectively. Both the median PFS and survival rate in the study group were higher than those in the control group. Conclusion In treating clinical stage I HCC, TACE combined with RFA and hepatic artery infusion of autologous CIK cells can improve QOL of patients, strengthen patient＇ s immune function, prolong the median PFS, and increase the overall survival rate.

关 键 词：原发性肝癌 肝动脉化疗栓塞术 射频消融术 自体细胞因子诱导的杀伤细胞 

分 类 号：R735.7[医药卫生—肿瘤]